Onconetix Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company specializing in men's health and oncology, has announced the completion of a private placement, raising approximately $12.9 million. The financing involved the issuance of Series D Convertible Preferred Stock and warrants to purchase up to 4,362,827 shares of common stock. Of the total amount raised, about $9.3 million was paid in cash, with the remainder used to offset existing obligations to certain investors. The Series D Preferred Stock is initially convertible into an equivalent number of common shares, subject to anti-dilution adjustments. The warrants have an exercise price of $3.6896 per share and will be exercisable for three years from the date of issuance. Proceeds from the offering will be used to settle debt with Veru, Inc., cover costs related to a terminated merger with Ocuvex, Inc., and for general corporate purposes and working capital.